Treatment of CTEPH and anticoagulation of choice

J. Barberà

Source: ERS Course 2019 - Masterclass in pulmonary embolism
Number: 10
Disease area: Pulmonary vascular diseases

WebcastPDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Barberà. Treatment of CTEPH and anticoagulation of choice. ERS Course 2019 - Masterclass in pulmonary embolism

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism
Source: Virtual Congress 2020 – Pulmonary embolism
Year: 2020


Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures
Source: Eur Respir Rev, 26 (145) 170020; 10.1183/16000617.0020-2017
Year: 2017



Effectiveness of thrombolytic therapy in pulmonary thromboembolism
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology
Year: 2007


Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Year: 2019

The use of new anticoagulants in CTEPH
Source: International Congress 2017 – PAH and CTEPH
Year: 2017


Management of recurrent PE in patients on anticoagulant therapy
Source: Virtual Congress 2021 – Pulmonary embolism: special situations
Year: 2021


Complications of anticoagulant therapy in patients with pulmonary thromboembolism
Source: Eur Respir J 2007; 30: Suppl. 51, 604s
Year: 2007

The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019


Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Source: Eur Respir J 2015; 45: 1142-1149
Year: 2015



Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018

Comparison of two regimens of oral anticoagulation in pulmonary embolism
Source: Eur Respir J 2006; 28: Suppl. 50, 632s
Year: 2006

Thrombolytic therapy in massive pulmonary thromboembolism
Source: Eur Respir J 2002; 20: Suppl. 38, 237s
Year: 2002

Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004


Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020


Thrombolytic therapy in cases with massive pulmonary thromboembolism
Source: Eur Respir J 2005; 26: Suppl. 49, 521s
Year: 2005

Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017


Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005

Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004


Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy
Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension
Year: 2019




Management of bleeding during anticoagulant therapy
Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress
Year: 2019